SCHEMBL627651

SCHEMBL627651

O=C(O)Cc1csc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
KDM4E B2RXH2 5/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
ALDH1A1 P00352 4/20 0.53
HPGD P15428 2/20 0.53
GAA P10253 2/20 0.53
HTT P42858 1/20 0.53
RHOC P08134 1/20 0.51
RHOA P61586 1/20 0.51
RXRA P19793 2/20 0.49
RXRB P28702 2/20 0.49
RXRG P48443 2/20 0.49
GABRA5 P31644 1/20 0.46
GABRB2 P47870 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SHMT2 P34897 1/20 0.46
TP53 P04637 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL628096 0.92 KDM4E (0.64) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL628748 0.91 LMNA (0.53) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL628071 0.91 LMNA (0.53) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL629217 0.89 KDM4E (0.51) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL628106 0.88 KDM4E (0.62) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL13148954 0.86 LMNA (0.47) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL5025486 0.86 LMNA (0.72) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL628077 0.84 RHOC (0.50) LMNAKDM4EALDH1A1HPGDGAA
SCHEMBL629535 0.80 LMNA (0.56) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL13148641 0.79 KDM4E (0.48) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-03-29 US disclosed
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-03-29 US disclosed
EP-2419412-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-02-22 EP disclosed
WO-2010120741-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) RBP4, RBP1, FABP4 LMNA 1913/4885KDM4E 751/4885SMN1; SMN2 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.